|
Age
|
1.02
|
0.885–1.18
|
0.751
| | | |
|
Gender (male/female)
|
1.18
|
0.197–7.08
|
0.855
| | | |
|
Never smoker (%)
|
0.857
|
0.104–7.04
|
0.886
| | | |
|
Body weight (kg)
|
0.931
|
0.861–1.01
|
0.0702
| | | |
|
Body mass index
|
0.704
|
0.519–0.955
|
0.0239
|
0.487
|
0.280–0.849
|
0.0111
|
|
Body surface area (DuBois, m2)
|
0.0418
|
0.000541–3.22
|
0.152
| | | |
|
Creatinine (mg/dL)
|
1.07
|
0.0280–40.7
|
0.972
| | | |
|
Krebs von den Lungen-6 (U/mL)
|
1
|
0.999–1.00
|
0.348
| | | |
|
Surfactant protein D (ng/dL)
|
0.995
|
0.989–1.00
|
0.08
|
0.997
|
0.990–1.00
|
0.315
|
|
Forced vital capacity (L)
|
0.561
|
0.150–2.1
|
0.391
| | | |
|
% Forced vital capacity (%)
|
0.967
|
0.918–1.02
|
0.213
| | | |
|
% DLco (%)
|
1.01
|
0.9580–1.06
|
0.739
| | | |
|
Administration period of Pirfenidone
|
1
|
0.999–1.00
|
0.329
| | | |
|
Time from pirfenidone discontinuation to nintedanib initiation
|
1.01
|
0.994–1.02
|
0.355
| | | |
|
Discontinued pirfenidone due to FVC decline
|
0.333
|
0.0751–1.48
|
0.148
| | | |
|
Anorexia during the period of pirfenidone
|
1.65
|
0.370–7.37
|
0.512
| | | |
|
Weight loss during the period of pirfenidone
|
2.93
|
0.657–13.1
|
0.159
| | | |
|
Weight loss with grade ≥ 2 during the period of pirfenidone
|
7.8
|
0.804–75.6
|
0.0764
|
3.29
|
0.184–58.8
|
0.418
|
